These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33417122)

  • 1. ASO Author Reflections: Using Tumor Genomics to Predict Axillary Response to Chemotherapy in Breast Cancer.
    James TA; Fan B
    Ann Surg Oncol; 2021 Mar; 28(3):1326-1327. PubMed ID: 33417122
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Role of Genomic Assay to Predict Neoadjuvant Chemotherapy Response in Breast Cancer.
    Pease AM; James TA
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):573-574. PubMed ID: 30783852
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer.
    Kantor O; King TA
    Ann Surg Oncol; 2021 Mar; 28(3):1368-1369. PubMed ID: 33389297
    [No Abstract]   [Full Text] [Related]  

  • 4. ASO Author Reflections: How Predictive Models Can Help Guide Axillary Surgery Decision Making After Neoadjuvant Chemotherapy.
    Davis J; Boughey JC
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):690-691. PubMed ID: 32725523
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Low Rates of Axillary Recurrence in Clinically Node-Positive Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy Alone Following Pathologic Response to Neoadjuvant Chemotherapy.
    Wong SM; Boileau JF
    Ann Surg Oncol; 2021 May; 28(5):2630-2631. PubMed ID: 33123855
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Omission of Axillary Lymph Node Dissection for Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy: Not Ready for Primetime?
    Almahariq MF; Chen PY; Dekhne N; Dilworth JT
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):869-870. PubMed ID: 32737699
    [No Abstract]   [Full Text] [Related]  

  • 7. ASO Author Reflections: Disparities in Outcome and Surgical Management Following Neoadjuvant Chemotherapy for Breast Cancer.
    Relation T; Oppong BA
    Ann Surg Oncol; 2021 Oct; 28(11):6498-6499. PubMed ID: 33660126
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era.
    Mamtani A; Morrow M
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):715-716. PubMed ID: 31468221
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Axillary Surgery for Breast Cancer: From Back to the Future, and Beyond.
    Lee J; Park HY
    Ann Surg Oncol; 2023 Aug; 30(8):4678-4679. PubMed ID: 36988751
    [No Abstract]   [Full Text] [Related]  

  • 10. ASO Author Reflections: Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy.
    Kim WH; Kim HJ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):644-645. PubMed ID: 30315382
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Limiting Axillary Surgery for Microinvasive Breast Cancer.
    James TA; Fan B
    Ann Surg Oncol; 2020 Oct; 27(11):4474. PubMed ID: 32488515
    [No Abstract]   [Full Text] [Related]  

  • 12. ASO Author Reflections: Advancing Surgical Care in Breast Cancer: Insights from an Axillary Surgery Referral Program.
    James TA; Roldan E
    Ann Surg Oncol; 2024 Mar; 31(3):1655. PubMed ID: 38055094
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: A Negative Axillary Clinical Exam Adequately Identifies Clinically Node-Positive Patients who Downstage After NAC and are Candidates for SLNB.
    Moo TA; Morrow M
    Ann Surg Oncol; 2019 Dec; 26(13):4244-4245. PubMed ID: 31617121
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: Axillary Surgery for Node-Positive Mastectomy Patients.
    Gaines S; Yao K
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):654-655. PubMed ID: 30327969
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Reducing Axillary Lymph Node Dissections in Node-Positive Breast Cancer Patients.
    van der Noordaa MEM; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):677-678. PubMed ID: 30474766
    [No Abstract]   [Full Text] [Related]  

  • 16. ASO Author Reflections: Moving Forward De-escalation of Axillary Surgery After Neoadjuvant Treatment in Breast Cancer.
    Rubio IT
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):638-639. PubMed ID: 30284130
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Is It Oncologically Safe?
    Piltin MA; Boughey JC
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):707-708. PubMed ID: 32737696
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: Axillary Staging in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy-Beyond Clinical Trials.
    Montagna G; Morrow M
    Ann Surg Oncol; 2020 Oct; 27(11):4523-4524. PubMed ID: 32500341
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: The Evolution of Axillary Management in Breast Cancer.
    Schwartz T; Marumoto AD; Giuliano AE
    Ann Surg Oncol; 2023 Feb; 30(2):1014-1015. PubMed ID: 36245054
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Rethinking Palpable Adenopathy as a Marker of High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer.
    Crown A; Morrow M
    Ann Surg Oncol; 2021 Oct; 28(11):6069-6070. PubMed ID: 33876356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.